A randomized, placebo-controlled phase II trial in HIV-1-infected, NRTI-, PI and NNRTI-experienced subjects to evaluate the safety, tolerability and efficacy of different doses of TMC125 [etravirine] b.i.d. on top of an individually optimized antiretroviral therapy by means of a 2-stage dose-escalating design

Trial Profile

A randomized, placebo-controlled phase II trial in HIV-1-infected, NRTI-, PI and NNRTI-experienced subjects to evaluate the safety, tolerability and efficacy of different doses of TMC125 [etravirine] b.i.d. on top of an individually optimized antiretroviral therapy by means of a 2-stage dose-escalating design

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2009

At a glance

  • Drugs Etravirine (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 01 Oct 2008 48-Week results published in full in Clinical Infectious Diseases 47: 969-978, No. 7, 1 Oct 2008.
    • 19 Oct 2007 Status changed from in progress to completed.
    • 16 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top